Does the media refer more to STTK or BEAM?

In the previous week, Shattuck Labs had 3 more articles in the media than Beam Therapeutics. MarketBeat recorded 11 mentions for Shattuck Labs and 8 mentions for Beam Therapeutics. Shattuck Labs' average media sentiment score of 0.43 beat Beam Therapeutics' score of 0.30 indicating that Shattuck Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Shattuck Labs 1 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Beam Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is IRON or STTK more profitable?

Disc Medicine's return on equity of -37.17% beat Shattuck Labs' return on equity. Company Net Margins Return on Equity Return on Assets Disc Medicine N/A -37.17% -33.65% Shattuck Labs N/A -43.57% -40.90%

Does the media prefer IRON or STTK?

In the previous week, Shattuck Labs had 9 more articles in the media than Disc Medicine. MarketBeat recorded 11 mentions for Shattuck Labs and 2 mentions for Disc Medicine. Shattuck Labs' average media sentiment score of 0.43 beat Disc Medicine's score of 0.00 indicating that Shattuck Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Disc Medicine 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Shattuck Labs 1 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is STTK or IMNM more profitable?

Shattuck Labs' return on equity of -43.57% beat Immunome's return on equity. Company Net Margins Return on Equity Return on Assets Shattuck Labs N/A -43.57% -40.90% Immunome N/A -50.56% -46.93%

Does the media favor STTK or IMNM?

In the previous week, Shattuck Labs and Shattuck Labs both had 11 articles in the media. Immunome's average media sentiment score of 0.62 beat Shattuck Labs' score of 0.43 indicating that Immunome is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Shattuck Labs 1 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immunome 3 Very Positive mention(s) 6 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is STTK or CLDX more profitable?

Shattuck Labs' return on equity of -43.57% beat Celldex Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Shattuck Labs N/A -43.57% -40.90% Celldex Therapeutics N/A -52.35% -47.61%

Does the media favor STTK or CLDX?

In the previous week, Shattuck Labs had 6 more articles in the media than Celldex Therapeutics. MarketBeat recorded 11 mentions for Shattuck Labs and 5 mentions for Celldex Therapeutics. Shattuck Labs' average media sentiment score of 0.43 beat Celldex Therapeutics' score of 0.20 indicating that Shattuck Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Shattuck Labs 1 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Celldex Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor STTK or NRIX?

In the previous week, Shattuck Labs had 5 more articles in the media than Nurix Therapeutics. MarketBeat recorded 11 mentions for Shattuck Labs and 6 mentions for Nurix Therapeutics. Shattuck Labs' average media sentiment score of 0.43 beat Nurix Therapeutics' score of 0.15 indicating that Shattuck Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Shattuck Labs 1 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nurix Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Shattuck Labs (STTK) Competitors

$5.86 -0.64 (-9.85%)

Closing price 04:00 PM Eastern

Extended Trading

$5.86 0.00 (-0.09%)

As of 04:20 PM Eastern

Compare

STTK vs. BEAM, IRON, IMNM, CLDX, and NRIX

Should you buy Shattuck Labs stock or one of its competitors? Shattuck Labs's main competitors and comparable companies include Beam Therapeutics (BEAM), Disc Medicine (IRON), Immunome (IMNM), Celldex Therapeutics (CLDX), and Nurix Therapeutics (NRIX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Shattuck Labs compare to Beam Therapeutics?

Shattuck Labs (NASDAQ:STTK) and Beam Therapeutics (NASDAQ:BEAM) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

Shattuck Labs has a net margin of 0.00% compared to Beam Therapeutics' net margin of -54.75%. Beam Therapeutics' return on equity of -30.71% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-43.57%	-40.90%
Beam Therapeutics	-54.75%	-30.71%	-24.07%

Shattuck Labs presently has a consensus target price of $13.33, suggesting a potential upside of 105.13%. Beam Therapeutics has a consensus target price of $49.00, suggesting a potential upside of 90.88%. Given Shattuck Labs' stronger consensus rating and higher probable upside, equities analysts plainly believe Shattuck Labs is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79

58.7% of Shattuck Labs shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by company insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Shattuck Labs has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.2, suggesting that its share price is 120% more volatile than the broader market.

Shattuck Labs has higher earnings, but lower revenue than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Shattuck Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	652.34	-$48.81M	-$0.51	N/A
Beam Therapeutics	$139.74M	18.97	-$79.99M	-$0.86	N/A

In the previous week, Shattuck Labs had 3 more articles in the media than Beam Therapeutics. MarketBeat recorded 11 mentions for Shattuck Labs and 8 mentions for Beam Therapeutics. Shattuck Labs' average media sentiment score of 0.43 beat Beam Therapeutics' score of 0.30 indicating that Shattuck Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shattuck Labs	1 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Beam Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Shattuck Labs beats Beam Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Shattuck Labs compare to Disc Medicine?

Disc Medicine (NASDAQ:IRON) and Shattuck Labs (NASDAQ:STTK) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

Shattuck Labs has higher revenue and earnings than Disc Medicine. Shattuck Labs is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$212.18M	-$6.58	N/A
Shattuck Labs	$1M	652.34	-$48.81M	-$0.51	N/A

Disc Medicine currently has a consensus price target of $110.18, indicating a potential upside of 73.98%. Shattuck Labs has a consensus price target of $13.33, indicating a potential upside of 105.13%. Given Shattuck Labs' stronger consensus rating and higher probable upside, analysts clearly believe Shattuck Labs is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00

Disc Medicine's return on equity of -37.17% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-37.17%	-33.65%
Shattuck Labs	N/A	-43.57%	-40.90%

Disc Medicine has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market. Comparatively, Shattuck Labs has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market.

83.7% of Disc Medicine shares are owned by institutional investors. Comparatively, 58.7% of Shattuck Labs shares are owned by institutional investors. 3.8% of Disc Medicine shares are owned by insiders. Comparatively, 8.8% of Shattuck Labs shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Shattuck Labs had 9 more articles in the media than Disc Medicine. MarketBeat recorded 11 mentions for Shattuck Labs and 2 mentions for Disc Medicine. Shattuck Labs' average media sentiment score of 0.43 beat Disc Medicine's score of 0.00 indicating that Shattuck Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Disc Medicine	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Shattuck Labs	1 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Shattuck Labs beats Disc Medicine on 10 of the 15 factors compared between the two stocks.

How does Shattuck Labs compare to Immunome?

Shattuck Labs (NASDAQ:STTK) and Immunome (NASDAQ:IMNM) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability, earnings and media sentiment.

Shattuck Labs has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market. Comparatively, Immunome has a beta of 2.55, indicating that its stock price is 155% more volatile than the broader market.

58.7% of Shattuck Labs shares are owned by institutional investors. Comparatively, 44.6% of Immunome shares are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by company insiders. Comparatively, 7.2% of Immunome shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Shattuck Labs' return on equity of -43.57% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-43.57%	-40.90%
Immunome	N/A	-50.56%	-46.93%

Shattuck Labs currently has a consensus target price of $13.33, suggesting a potential upside of 105.13%. Immunome has a consensus target price of $34.25, suggesting a potential upside of 61.79%. Given Shattuck Labs' stronger consensus rating and higher probable upside, equities research analysts clearly believe Shattuck Labs is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
Immunome	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

Shattuck Labs has higher earnings, but lower revenue than Immunome. Shattuck Labs is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	652.34	-$48.81M	-$0.51	N/A
Immunome	$6.94M	346.47	-$212.39M	-$2.53	N/A

In the previous week, Shattuck Labs and Shattuck Labs both had 11 articles in the media. Immunome's average media sentiment score of 0.62 beat Shattuck Labs' score of 0.43 indicating that Immunome is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shattuck Labs	1 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immunome	3 Very Positive mention(s)	6 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Shattuck Labs beats Immunome on 10 of the 15 factors compared between the two stocks.

How does Shattuck Labs compare to Celldex Therapeutics?

Shattuck Labs (NASDAQ:STTK) and Celldex Therapeutics (NASDAQ:CLDX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

58.7% of Shattuck Labs shares are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by insiders. Comparatively, 5.2% of Celldex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Shattuck Labs had 6 more articles in the media than Celldex Therapeutics. MarketBeat recorded 11 mentions for Shattuck Labs and 5 mentions for Celldex Therapeutics. Shattuck Labs' average media sentiment score of 0.43 beat Celldex Therapeutics' score of 0.20 indicating that Shattuck Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shattuck Labs	1 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Celldex Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Shattuck Labs has higher earnings, but lower revenue than Celldex Therapeutics. Shattuck Labs is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	652.34	-$48.81M	-$0.51	N/A
Celldex Therapeutics	$1.54M	1,661.88	-$258.76M	-$4.35	N/A

Shattuck Labs presently has a consensus price target of $13.33, suggesting a potential upside of 105.13%. Celldex Therapeutics has a consensus price target of $61.92, suggesting a potential upside of 90.01%. Given Shattuck Labs' stronger consensus rating and higher possible upside, equities research analysts clearly believe Shattuck Labs is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Shattuck Labs has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market.

Shattuck Labs' return on equity of -43.57% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-43.57%	-40.90%
Celldex Therapeutics	N/A	-52.35%	-47.61%

Summary

Shattuck Labs beats Celldex Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Shattuck Labs compare to Nurix Therapeutics?

Shattuck Labs (NASDAQ:STTK) and Nurix Therapeutics (NASDAQ:NRIX) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Shattuck Labs has higher earnings, but lower revenue than Nurix Therapeutics. Shattuck Labs is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	652.34	-$48.81M	-$0.51	N/A
Nurix Therapeutics	$83.98M	28.27	-$264.46M	-$3.45	N/A

In the previous week, Shattuck Labs had 5 more articles in the media than Nurix Therapeutics. MarketBeat recorded 11 mentions for Shattuck Labs and 6 mentions for Nurix Therapeutics. Shattuck Labs' average media sentiment score of 0.43 beat Nurix Therapeutics' score of 0.15 indicating that Shattuck Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shattuck Labs	1 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nurix Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

58.7% of Shattuck Labs shares are held by institutional investors. 8.8% of Shattuck Labs shares are held by insiders. Comparatively, 6.7% of Nurix Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Shattuck Labs has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -928.44%. Shattuck Labs' return on equity of -43.57% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-43.57%	-40.90%
Nurix Therapeutics	-928.44%	-76.09%	-57.31%

Shattuck Labs presently has a consensus target price of $13.33, indicating a potential upside of 105.13%. Nurix Therapeutics has a consensus target price of $34.21, indicating a potential upside of 49.54%. Given Shattuck Labs' stronger consensus rating and higher possible upside, research analysts clearly believe Shattuck Labs is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Shattuck Labs has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market. Comparatively, Nurix Therapeutics has a beta of 1.82, suggesting that its stock price is 82% more volatile than the broader market.

Summary

Shattuck Labs beats Nurix Therapeutics on 13 of the 17 factors compared between the two stocks.

Get Shattuck Labs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STTK vs. The Competition

Export

Metric	Shattuck Labs	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$588.13M	$3.81B	$7.10B	$13.40B
Dividend Yield	N/A	3.65%	2.54%	17.38%
P/E Ratio	-11.49	13.23	273.67	26.20
Price / Sales	588.13	1,214.22	595.47	86.09
Price / Cash	N/A	39.04	27.22	34.74
Price / Book	4.51	16.78	11.09	6.35
Net Income	-$48.81M	-$23.16M	$3.49B	$381.26M
7 Day Performance	-10.40%	-3.99%	-2.28%	-0.61%
1 Month Performance	-13.70%	-12.01%	-7.03%	-4.83%
1 Year Performance	126.25%	14.71%	5.66%	1.12%

Shattuck Labs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STTK Shattuck Labs	2.4574 of 5 stars	$5.86 -9.8%	$13.33 +127.5%	+176.6%	$588.13M	$1M	N/A	40
BEAM Beam Therapeutics	2.4195 of 5 stars	$24.52 +1.2%	$49.00 +99.8%	-0.3%	$2.53B	$139.74M	N/A	540	Analyst Upgrade Gap Up
IRON Disc Medicine	2.2675 of 5 stars	$65.87 +1.5%	$110.18 +67.3%	-6.6%	$2.53B	N/A	N/A	165
IMNM Immunome	2.8616 of 5 stars	$21.89 +1.0%	$35.18 +60.7%	+71.0%	$2.49B	$6.94M	N/A	177	Analyst Downgrade
CLDX Celldex Therapeutics	2.0573 of 5 stars	$31.64 +0.5%	$61.92 +95.7%	+23.4%	$2.48B	$1.54M	N/A	198

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:STTK) was last updated on 10/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Shattuck Labs (STTK) Competitors

STTK vs. BEAM, IRON, IMNM, CLDX, and NRIX

How does Shattuck Labs compare to Beam Therapeutics?

Summary

How does Shattuck Labs compare to Disc Medicine?

Summary

How does Shattuck Labs compare to Immunome?

Summary

How does Shattuck Labs compare to Celldex Therapeutics?

Summary

How does Shattuck Labs compare to Nurix Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STTK vs. The Competition

Shattuck Labs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Shattuck Labs (STTK) Competitors

STTK vs. BEAM, IRON, IMNM, CLDX, and NRIX

How does Shattuck Labs compare to Beam Therapeutics?

Is STTK or BEAM more profitable?

Do analysts prefer STTK or BEAM?

Do institutionals and insiders have more ownership in STTK or BEAM?

Which has more risk & volatility, STTK or BEAM?

Which has better earnings & valuation, STTK or BEAM?

Does the media refer more to STTK or BEAM?

Summary

How does Shattuck Labs compare to Disc Medicine?

Which has stronger earnings and valuation, IRON or STTK?

Do analysts recommend IRON or STTK?

Is IRON or STTK more profitable?

Which has more risk & volatility, IRON or STTK?

Do institutionals & insiders believe in IRON or STTK?

Does the media prefer IRON or STTK?

Summary

How does Shattuck Labs compare to Immunome?

Which has more volatility & risk, STTK or IMNM?

Do institutionals & insiders hold more shares of STTK or IMNM?

Is STTK or IMNM more profitable?

Do analysts rate STTK or IMNM?

Which has preferable valuation & earnings, STTK or IMNM?

Does the media favor STTK or IMNM?

Summary

How does Shattuck Labs compare to Celldex Therapeutics?

Do institutionals and insiders have more ownership in STTK or CLDX?

Does the media favor STTK or CLDX?

Which has stronger earnings & valuation, STTK or CLDX?

Do analysts prefer STTK or CLDX?

Which has more risk & volatility, STTK or CLDX?

Is STTK or CLDX more profitable?

Summary

How does Shattuck Labs compare to Nurix Therapeutics?

Which has better earnings & valuation, STTK or NRIX?

Does the media favor STTK or NRIX?

Do institutionals & insiders believe in STTK or NRIX?

Is STTK or NRIX more profitable?

Do analysts prefer STTK or NRIX?

Which has more risk and volatility, STTK or NRIX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STTK vs. The Competition

Shattuck Labs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools